Rezdiffra(Resmetirom) Side Effects

Common adverse reactions include diarrhea (33% EAIR), nausea (15-18%), pruritus (10%), vomiting (8%), and dizziness (4%).

Gastrointestinal and Systemic Adverse Events

In clinical trials, gastrointestinal effects (diarrhea, nausea, vomiting) were dose-dependent, typically occurring early and lasting weeks. Hepatobiliary events (cholelithiasis, acute cholecystitis) had low incidence (<1/100 PY). Lab abnormalities included transient ALT/AST elevations (≤13% >3x ULN) and decreased FT4 (17% at 100 mg). Serious risks included drug-induced autoimmune-like hepatitis (1 case) and statin-related myopathy. Hypersensitivity reactions (rash, urticaria) and rare arrhythmias were noted. Long-term safety in cirrhosis is not specified in the description.

Resmetirom(Rezdiffra)
REZDIFFRA is indicated for Noncirrhotic nonalcoholic steatohepatitis (NASH).
RELATED ARTICLES
How effective is Resmetirom(Rezdiffra)?

Resmetirom is manufactured by Madrigal in the United States, and in mid-July 2023, Madrigal submitted a...

Thursday, June 26th, 2025, 17:00
/ 1
1 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved